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Overweight across the life course and adipokines,
inﬂammatory and endothelial markers at age 60–64 years:
evidence from the 1946 birth cohort
ET Murray1, R Hardy2, A Hughes3, A Wills4, N Sattar5, J Deanﬁeld6, D Kuh2, P Whincup1 and the NSHD Scientiﬁc and Data Collection team
BACKGROUND/OBJECTIVES: There is growing evidence that early development of obesity increases cardiovascular risk later in life,
but less is known about whether there are effects of long-term excess body weight on the biological drivers associated with the
atherosclerotic pathway, particularly adipokines, inﬂammatory and endothelial markers. This paper therefore investigates the
inﬂuence of overweight across the life course on levels of these markers at retirement age.
SUBJECTS/METHODS: Data from the Medical Research Council National Survey of Health and Development (n= 1784) were used
to examine the associations between overweight status at 2, 4, 6, 7, 11, 15, 20, 26, 36, 43, 53 and 60–64 years (body mass index
(BMI)⩾ 25 kgm− 2 for adult ages and gender-speciﬁc cut-points for childhood ages equivalent to BMI⩾ 25 kgm− 2) and
measurements of adipokines (leptin and adiponectin), inﬂammatory markers (C-reactive protein (CRP), interleukin-6 (IL-6)) and
endothelial markers (E-selectin, tissue plasminogen activator (t-PA) and von Willebrand factor) at 60–64 years. In addition, the ﬁt of
different life course models (sensitive periods/accumulation) were compared using partial F-tests.
RESULTS: In age- and sex-adjusted models, overweight at 11 years and onwards was associated with higher leptin, CRP and IL-6
and lower adiponectin; overweight at 15 years and onwards was associated with higher E-selectin and t-PA. Associations between
overweight at all ages earlier than 60–64 with leptin, adiponectin, CRP and IL-6 were reduced but remained apparent after
adjustment for overweight at 60–64 years; whereas those with E-selectin and t-PA were entirely explained. An accumulation model
best described the associations between overweight across the life course with adipokines and inﬂammatory markers, whereas for
the endothelial markers, the sensitive period model for 60–64 years provided a slightly better ﬁt than the accumulation model.
CONCLUSIONS: Overweight across the life course has a cumulative inﬂuence on adipokines, inﬂammatory and possibly endothelial
markers. Avoidance of overweight from adolescence onwards is likely important for cardiovascular disease prevention.
International Journal of Obesity (2015) 39, 1010–1018; doi:10.1038/ijo.2015.19
INTRODUCTION
Overweight and obesity represent a major global health problem;
the World Health Organization estimated that in 2008, more
than 1.4 billion adults were overweight (body mass index (BMI)
25–29 kgm− 2) and 500 million obese (BMI430 kgm− 2) globally.1
It has been calculated that if all persons were not overweight or
obese, ~ 3.4 million (6.4%) of all deaths annually,2 and approxi-
mately a quarter of all deaths due to ischaemic heart disease could
be prevented;1 the largest single cause of death.3
In recent years, the mechanism(s) by which excess body weight
produces adverse cardiovascular outcomes has attracted interest,
with one potential pathway being the dysfunction of adipose
tissue.4,5 When energy balance is positive, more calories are
consumed than expended, adipocytes ﬁll up with fatty acids, and
patterns of adipokine secretion are altered; leptin secretion rises
and adiponectin declines. The rising concentration of leptin is
associated with higher levels of inﬂammatory cytokines, which
have been implicated in localised inﬂammation and facilitate
cholesterol accumulation (hallmarks of the atherosclerotic
process). Lower adiponectin levels may lead to an impaired ability
to repair endothelial damage and inhibit the endothelial inﬂam-
matory response, but this is an area of ongoing research.4–7
A notable feature of the global obesity epidemic is the
appearance of overweight and obesity in childhood and early
adulthood.8 There is growing evidence that the early development
of obesity increases cardiovascular risk later in life,9–11 but less is
known about whether there are persistent effects of long-term
excess body weight on the biological drivers associated with the
atherosclerotic pathway, particularly adipokines, inﬂammatory and
endothelial markers, which have collectively been referred to as
‘adiposopathic markers’7 because their secretion is associated with
adipose tissue hypertrophy. Numerous studies have documented
cross-sectional associations between higher levels of adiposity
and adverse levels of these ‘adiposopathic’ markers, in mid to late
adulthood,12,13 with relatively short-term changes in weight
altering the levels of these factors.14–18 A few studies have shown
that weight gain from adolescence to young adulthood, and from
early to mid-adulthood, are associated with higher levels of
inﬂammatory marker C-reactive protein (CRP) at ages 18, (ref.19)
22 (ref.20) and 31 years.21 However, it is not clear how much
adiposity levels before middle age affect levels of adiposopathic
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markers in later life, and whether any inﬂuence reﬂects a
cumulative process or the inﬂuence of adiposity at speciﬁc
sensitive periods. If it can also be shown that levels of other
inﬂammatory markers, plus adipokines and endothelial markers,
are associated with excess body weight at similar ages in the life
course, this would give additional support to the hypothesis that
adipose tissue dysfunction is one of the pathways by which
overweight and obesity lead to cardiovascular disease (CVD).
We have therefore used data from the Medical Research Council
National Survey of Health and Development (NSHD) to explore at
what stage in the life course overweight is associated with
adiposopathic markers of adipokines (leptin and adiponectin),
inﬂammatory (CRP, interleukin-6 (IL-6) and endothelial markers
(E-selectin, tissue plasminogen activator (t-PA) and von Willebrand
factor (vWF)) measured in early old age (60–64 years). Our aims
were to: (1) determine how early in the life course being
overweight is associated with each adiposopathic marker; (2)
identify whether being overweight at a particular age, or at
multiple ages (particularly including adolescence, early adult and
later adult), best describes the relationship between overweight
across life and each adiposopathic marker; and (3) given the
ﬁndings of aim 2, whether associations of the chosen model are
independent of potential confounders of smoking, childhood
social class and adult social class. We have treated overweight as a
dichotomous variable, to facilitate the life course analytic
approach used in this paper, and to deﬁne the speciﬁc impact
of overweight as commonly deﬁned (BMI⩾ 25 kgm− 2).
MATERIALS AND METHODS
Study design
The Medical Research Council NSHD is a socially stratiﬁed British cohort of
individuals who have been followed up 23 times between birth and late
middle age.22 The original cohort comprised 5362 singleton children born
during 1 week in March 1946. At the most recent clinic assessment at
60–64 years (2006–2010), eligible cohort members (those known to be
alive and with a known address in England, Scotland or Wales) were
invited for an assessment at one of the six clinical research facilities (CRFs)
or to be visited by a research nurse at home. Invitations were not sent to
those who had died (n= 778, 14.5% of the original cohort), who had
emigrated (570, 10.6%), who were lost to follow-up (594, 11.1%) and who
had previously withdrawn from the study (564, 10.5%). Of the 2856 cohort
members invited, 1690 (59.2%) attended a CRF for full examination and
539 (18.9%) were examined at home by a trained nurse.23 Ethical approval
was given by the Central Manchester Research Ethics Committee for
genetic studies of lifelong health, disease and ageing (07/H1008/168) and
the Scottish A Research Ethics Committee.
Life course BMI
Heights (m) and weights (kg) were measured by trained observers in a
standardised manner at 2, 4, 6, 7, 11, 15, 36, 43, 53 and 60–64 years, and
were self-reported by cohort members at 20 and 26 years. BMI was
calculated (kg m− 2) at each age, with ‘overweight’ deﬁned according to
the World Health Organization guidelines as a BMI⩾ 25 kgm− 2 for adult
ages and gender-speciﬁc cut-points for childhood ages (2–15 years)
equivalent to a BMI⩾ 25 kgm− 2 at age 18 years.24
Measurement of adiposopathic markers at 60–64 years
Overnight fasting blood samples were taken during the clinic or home visit
and initially processed at the CRF laboratories. Aliquots were frozen and
stored before being transferred to the Medical Research Council Human
Nutrition Research Laboratory in Cambridge where analyses of inﬂamma-
tory marker CRP was processed according to standardised protocols.
Analyses of adipokines (leptin and adiponectin), endothelial markers
(E-selectin and t-PA) and inﬂammatory marker IL-6 were undertaken by
British Heart Foundation Research Centre in Glasgow. The method and
commercial assay, plus interassay coefﬁcients of variations are given in
Supplementary Table S1. Age at measurement in months was recorded.
Covariates
Information on smoking status, occupational social class and disease
conditions were obtained by questionnaire at 60–64 years; cigarette
smoking was classiﬁed into three categories: never, former and current.
Father’s occupation when the cohort member was age 4 years and own
occupational class at age 53 years were chosen to represent childhood and
adult socioeconomic positions, respectively. The Registrar General’s six-
group classiﬁcation25 was collapsed into four groups: professional and
intermediate (I and II); skilled non-manual (IIInm); skilled manual (IIIm); and
semiskilled and unskilled manual (IV and V). Wherever possible, missing
values were imputed from adjacent ages (33 values from age 11 and 14
values from age 15 for childhood social class; 107 values from age 36 for
early adulthood; 107 values from age 43 for late adulthood). Stroke and
CVD diagnoses (angina or myocardial infarction) were based on participant
responses indicating at age 53 or 60–64 years whether a doctor had ever
diagnosed them with the condition.26
Statistical analysis
Analyses were undertaken using STATA version 12 (STATA corp LP, TX,
USA). All adipokines, endothelial and inﬂammatory markers were positively
skewed and therefore transformed using the natural logarithm to achieve
normality of their distributions. This analysis comprises three parts aimed
at investigating when in the life course excessive body weight may explain
differences in the adiposipathic markers examined at the age of 60–64
years. First, age-adjusted models were ﬁtted for each novel risk factor
linearly regressed on BMI at each age (2, 4, 6, 7, 11, 15, 20, 26, 36, 43, 53
and 60–64 years) separately. Linearity of associations was assessed using
scatterplots and Lowess smoothed curves. The same models were then
ﬁtted using dichotomised ‘overweight’ and ‘normal weight’ categories
using established, worldwide deﬁnitions at each age. This dichotomous
approach also facilitated the ﬁtting of life course models, as described
below. Each natural logarithm-transformed coefﬁcient was multiplied by
100 to express all regression coefﬁcients as mean percentage differences27
in each adiposopathic marker for overweight compared with non-
overweight cohort members. Gender differences in the relationships
between overweight at each age and each adiposipathic marker were
investigated by testing interactions between sex and overweight and
assessing associations separately for men and women. Each model was
then adjusted for overweight status at 60–64 years in order to test the
extent of mediation of earlier life overweight by later overweight. As few
participants were classiﬁed as obese (430 BMI) before age 43, sensitivity
analyses were conducted by replacing the ‘overweight’ BMI cut-off value
with the alternative level of 27.5 kgm− 2 (and equivalent levels for
childhood ages24). In addition, models were reﬁtted as categorical
variables comprising normal weight (o25 kgm− 2), overweight (25–29.9)
and obese (⩾30), at ages 43, 53 and 60–64.
Second, a structured modelling approach28 was used to examine
different hypothesised life course overweight models in relation to each
adiposopathic marker. The basic premise of the approach is to compare
the model ﬁt of a set of nested life course models with a saturated model
containing all possible main effects and interactions. The original paper
proposed the use of the F-test to compare the ﬁt of each reduced model
with the saturated model. A P-value that was not statistically signiﬁcant
(P40.05) indicates that there is no evidence that the more complex model
explained the data better than the simpler life course model. We also
assessed model ﬁt using Akaike Information Criteria (AIC), where a smaller
AIC indicated a better model ﬁt. To avoid zero cell counts in trajectory
groups, and to reduce potential multi-colinearity of repeated overweight
measurements (Supplementary Table S2), overweight categories at three
ages were chosen to represent adolescence (15 years), mid-adulthood (36
years) and early old age (60–64 years) for this section of the analyses;
resulting in eight possible trajectories. We did not include overweight
status for childhood ages in life course models, as the prevalence of
overweight before puberty was low in this cohort. In the main analysis, the
life course models analysed were as follows: (1) sensitive period models for
adolescence, mid-adulthood or early old age; and (2) accumulation of risk
models of overweight in adolescence and mid-adulthood only, mid-
adulthood and early old age only, and across all the three time periods.
The three age accumulation models were then split further into a ‘relaxed’
accumulation model where associations of overweight at each age can
have different strengths, whereas a ‘strict’ accumulation model indicated
strengths of association were equal for all three ages. When there was
evidence that two or more life course models for a given outcome
provided as good a ﬁt as the saturated model, we selected the model with
Life course overweight and adiposipathic markers
ET Murray et al
1011
© 2015 Macmillan Publishers Limited International Journal of Obesity (2015) 1010 – 1018
the lowest AIC. When the null model ﬁtted the data as well as the saturated
model, the null model was selected. Sensitivity analysis was conducted
separately replacing overweight at 15 with 20 years, age 36 with 26 or 43
years and age 60–64 with 53 years.
For the third part of the analyses, the best ﬁtting life course model with
adjustment for sex and age (in months) were then subsequently adjusted
for smoking, and childhood and adulthood socioeconomic positions. To
assess whether associations could be explained by disease status, all
models were re-run after separate exclusion of prevalent CVD cases
(n=151) and CRP levels indicative of acute infection (410mg l− 1; n=107)
at age 60–64 years. To investigate bias due to missing data, the main
analysis was repeated with added imputed values from 50 imputed
datasets obtained via chained equations, using 10 cycles per data set.29
The imputation model included all variables used in models (BMI at all
ages, adiponectin, leptin, t-PA, E-selectin, vWF, CRP, IL-6, age, sex, CVD or
stroke at age 60–64 years, smoking status 60–64 years, childhood
socioeconomic position and adult socioeconomic position). Cohort
members who had died before or during the most recent data collection
(at age 60–64 years), or who were missing any adiposopathic markers,
were excluded from the multiple imputation analysis.
RESULTS
Of the 2229 participants with a clinic or home visit at 60–64 years,
1784 (80.0%) had complete measurements for all seven adiposo-
pathic markers. Those included were slightly younger in age at the
time of assessment (63.2 vs 64.0 years), more likely to have
attended the clinic than had a home visit (87.3% vs 29.7%), more
likely to be in a non-manual childhood socioeconomic position
(49.0% vs 43.6%) and adult socioeconomic position (72.6% vs
61.0%), and less likely to be overweight (⩾25 kgm− 2) at 36 years
(31.2% vs 36.6%), 53 years (69.5% vs 76.2%) and 63 years
(69.5% vs 76.2%; data not shown). Distribution of the adiposo-
pathic markers and covariates at age 60–64 years, and the
proportion of study members who were overweight at each age,
are shown in Table 1, total and by gender.
Figures 1–3 show age- and sex-adjusted models for overweight
at each age, ﬁtted separately, and each adiposopathic marker: the
adipokines adiponectin and leptin in Figure 1, the endothelial
markers E-selectin and t-PA in Figure 2 and the inﬂammatory
markers CRP and IL-6 in Figure 3. Estimates and P-values are
displayed separately in Supplementary Table S4. Greater BMI and
overweight at 11 years and onwards tended to be associated with
lower adiponectin and higher leptin, CRP and IL-6; higher BMI and
overweight at 15 years and onwards tended to be associated with
higher E-selectin and t-PA. Strengths of associations also tended
to increase the older the age at which overweight was measured.
For example, participants overweight at age 11 had mean leptin
levels 50.0% (30.3–72.6%) higher than participants who were not
overweight at age 11, whereas percentage differences had
increased to 75.1% (58.9–92.9%) for overweight at age 26 years
and to 146.6% (130.8–163.5%) at 60–64 years. Before the age of
11, the only association consistent with those at later ages was
that between overweight at age 2 and higher CRP (12.7% (2.5–
24.0%)). vWF was only associated with overweight at the age of 6
years, but not at later ages. The associations between overweight
earlier than 60–64 years with leptin, adiponectin, CRP and IL-6
were reduced but remained apparent after adjustment for
overweight at age 60–64 years; whereas E-selectin and t-PA were
entirely explained. Results using BMI modelled as a continuous
measure and those using the cut-off for overweight found similar
associations, with the exception that associations of BMI and
vWF were apparent at some adult ages when BMI was modelled
Table 1. Description of study members in the 1946 British Birth cohort with complete data on adiposopathic markers at age 60–64 years
Total Men Women P-value sex
difference
N Mean (s.d.) N Mean (s.d.) N Mean (s.d.)
Mean age (years) 1777 63.2 (1.1) 868 63.1 (1.2) 909 63.2 (1.1) 0.14
Mean adiponectin (ugml− 1)a 1784 2.5 (0.7) 873 2.2 (0.7) 911 2.8 (0.6) o0.01
Mean leptin (ngml− 1)a 1784 2.5 (0.9) 873 2.0 (0.8) 911 3.0 (0.8) o0.01
Mean E-selectin (ngml− 1)a 1784 3.6 (0.5) 873 3.6 (0.5) 911 3.5 (0.4) o0.01
Mean t-PA (ngml− 1)a 1784 2.1 (0.6) 873 2.2 (0.6) 911 2.1 (0.6) o0.01
Mean vWF (IUml− 1)a 1784 4.8 (0.5) 873 4.8 (0.5) 911 4.8 (0.5) 0.83
Mean CRP (mg l− 1)a 1781 0.8 (0.9) 872 0.8 (0.9) 909 0.9 (0.9) 0.12
Mean IL-6 (pgml− 1)a 1784 0.7 (0.7) 873 0.7 (0.7) 911 0.7 (0.7) 0.05
Overweight (obese, years), n (%)b
2 1397 35.2 (15.2) 692 33.8 (16.5) 705 36.5 (13.9) 0.3
4 1551 20.3 (5.5) 762 20.7 (6.7) 789 19.8 (4.4) 0.64
6 1461 10.5 (0.8) 719 9.7 (0.6) 742 11.3 (1.1) 0.32
7 1502 7.5 (0.8) 738 5.6 (0.3) 764 9.3 (0.8) 0.01
11 1508 8.0 (0.8) 741 6.6 (0.7) 767 9.3 (0.9) 0.06
15 1384 8.6 (0.6) 683 6.9 (0.4) 701 10.3 (0.7) 0.03
20 1464 11.7 (1.0) 701 13.1 (0.4) 763 10.4 (1.6) 0.1
26 1567 18.0 (1.8) 759 23.1 (2.0) 808 13.2 (1.6) o0.01
36 1624 31.2 (4.3) 792 40.9 (3.9) 832 21.9 (4.6) o0.01
43 1677 44.3 (9.6) 819 52.8 (8.6) 310 36.1 (10.6) o0.01
53 1701 65 (20.9) 823 71.2 (19.7) 878 59.3 (22.0) o0.01
60–64 1781 69.5 (27.5) 871 73.9 (26.6) 910 65.3 (28.4) o0.01
CVD (%) 1711 8.8 828 11.5 883 6.3 o0.01
Current smoker (%) 1634 10.8 796 10.3 838 11.3 0.5
Ex-smoker (%) 1634 41.1 796 48.1 838 34.4 o0.01
Manual CSEP (%) 1699 53 835 53.5 864 52.6 0.68
Manual ASEP (%) 1774 27.4 866 32 908 23 o0.01
Abbreviations: ASEP, adult socioeconomic position; BMI, body mass index; CRP, C-reactive protein; CSEP, childhood socioeconomic position; CVD,
cardiovascular disease; IL-6, interleukin-6; t-PA, tissue plasminogen activator; vWF, von Willebrand factor. aGeometric mean. bOverweight=BMI⩾ 25 kgm− 2;
obese= BMI⩾ 30 kgm− 2.
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as a continuous variable but not as a dichotomised variable
(Supplementary Table S3).
Estimates using the alternative BMI cut-off of 27.5 kg m− 2 were
higher, but conﬁdence intervals were wider (Supplementary Table
S5). With the exception of vWF, models for ages 43, 53 and 60–64
years reﬁtted as three categories of BMI, showed that relationships
were dose related with both overweight and obese groups having
mean adiponectin, leptin, CRP, IL-6, E-selectin and t-PA values
worse than normal weight participants, but with effects stronger
for obese participants (Supplementary Table S6).
Interaction tests were also carried out to examine whether the
associations between being overweight at any age and adiposo-
pathic markers differed by gender (Supplementary Table S7).
There was some evidence that the associations between over-
weight at adult ages and inﬂammatory markers (CRP and IL-6)
varied by gender, though no other adiposipathic markers showed
consistent gender interaction. The main results were therefore
presented for both genders combined. Gender-speciﬁc analyses
of the associations between overweight at each age, ﬁtted
separately, and CRP and IL-6 indicated that the pattern of
relationships was apparent for both genders but stronger in
women; among whom independent associations between BMI in
early adult life and adiposipathic markers were observed even
after adjustment for BMI at 63 years (Supplementary Table S8).
In order to compare the ﬁt of the different life course models,
the sample was restricted further to participants who had BMI
measurements at three speciﬁc age points, chosen to represent
adolescence (15 years), early adulthood (36 years) and early old
age (60–64 years; n= 1280, 71.7%). Associations of overweight at
each age with adiposopathic makers were almost identical, and
interpretations unchanged, in the reduced sample (data not
shown). Over the three ages, a total of 354 (27.7%) of participants
were never overweight and 323 (25.5%) were only overweight at
age 60–64 years. Among 537 (42.0%) study members who ﬁrst
became overweight at age 15 or 36 years (n= 537), 474 (88.2%)
subsequently remained overweight.
With adjustments for age and sex, the model where risk
accumulated across all three life periods stood out as the best
model to describe the relationship between life course overweight
and the adipokines and inﬂammatory markers. For vWF, there was
no evidence that the null model provided a poorer ﬁt than
the saturated model and so it was concluded that there was no
effect of overweight at any age on vWF at age 60–64 years.
Accumulation models including overweight at all three ages ﬁtted
the data as well as the saturated models for all other markers. The
AIC for the model constraining the effect of overweight to be
constant at all ages (‘strict’ accumulation model) had the lowest
AIC for IL-6 and the model allowing the effect to vary across the
three age points (`relaxed’ accumulation) the lowest for leptin and
CRP (Table 2). For the endothelial markers, E-selectin and t-PA, as
well as for adiponectin, although the ‘relaxed’ accumulation model
explained the data as well as the saturated model, the early old
age sensitive period model had slightly smaller AICs. For
consistency across types of markers, we thus investigated the
relaxed accumulation model further for the adipokines and
the inﬂammatory markers and the early old age model for the
endothelial markers E-selectin and t-PA. We also investigated the
early old age model for adiponectin and the strict accumulation
model for adiponectin as the best ﬁtting models according to
the AIC.
Details of the selected life course models controlling for age, sex
and potential confounders of smoking, childhood socioeconomic
position and adult socioeconomic position are shown in Table 3.
For adiponectin, leptin and CRP, after adjustment for overweight
at the other two ages, the strengths of association with
overweight increased with age. For IL-6, overweight at 60–64
Figure 1. Percentage difference (95% CI) in adipokines at age 60–64 years for overweight (BMI425 kgm− 2) vs normal weight, ﬁtted separately
for each age. Black lines indicate adjustment for age and sex only. Grey lines indicate further adjustment for overweight status at age 60–64
years. CI, conﬁdence interval.
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years had the strongest association, followed by overweight at 15
years and then at 36 years. E-selectin and t-PA were, respectively,
16.2% (10.2, 22.5) and 34.3% (25.2, 44.0) higher for participants
who were overweight compared with those not overweight at the
age of 60–64 years. Adjustment for smoking status at age 60–64
years increased the strength of these associations slightly for
adiponectin, CRP, E-selectin and IL-6, whereas adjustment for both
childhood and adulthood socioeconomic measures reduced these
associations slightly, but relationships remained strong after full
adjustment.
All results were similar when alternative ages (20 rather than 15
years, 26 or 43 rather than 36 years, and 53 rather than 60–64
years) were used to test the ﬁt of life course overweight models
(data not shown). Exclusion of participants with CRP levels
indicative of acute infection (⩾10) eliminated associations of
overweight at age 2 with CRP and adiponectin but did not
substantially alter other associations or life course modelling
conclusions (data not shown). Excluding those with a self-report of
CVD or stroke at age 53 or 60–64 years only altered associations
slightly, both higher and lower, with interpretation of results not
changed (data not shown). Results from models using multiple
imputations were largely consistent with results from the
complete case analyses. Associations of adiponectin with over-
weight at 2 years and e-selectin with 15 years were attenuated in
the multiple imputation analysis, while associations of adiponectin
and e-selectin with overweight at 20 years were apparent in
the multiple imputation and not the complete case analysis
(Supplementary Table S9).
DISCUSSION
In this cohort of British men and women followed prospectively
from birth in 1946 until age 60–64 years, greater accumulation of
overweight across adolescence and adulthood was associated
with higher adverse levels of several adiposopathic markers,
particularly adipokines and inﬂammatory markers, which are
closely implicated in the development of the atherosclerotic
process. A slightly different pattern was seen for the endothelial
makers of E-selectin and t-PA, where overweight at 60–64 years
was particularly important.
The ﬁnding that overweight status was associated with levels of
adiponectin, leptin, CRP and IL-6 is consistent with many previous
studies showing that excess body fat in adulthood is associated
cross-sectionally with adverse levels of these adipokines12,13,20 and
inﬂammatory markers.15,18 However, the current analyses extend
earlier reports by including a wider range of adiposopathic
markers, including markers of endothelial dysfunction. We were
able to show that, even though all of the outcomes measured for
this study are a part of the same adiposopathic pathway,
differences between overweight and non-overweight study
members were much larger for leptin than the other markers.
This could be explained by the fact that leptin is a very strong
marker of total body fat status and a key regulator of energy
intake and expenditure through appetite, metabolism and
behaviour.6 Adiponectin is also directly released by adipose tissue,
but is less directly related to body fat, potentially because of
differences in how each adipokine is expressed in fat cells,
structure and regulation. As the changes in inﬂammatory and
endothelial marker concentrations could be a consequence of the
Figure 2. Percentage difference (95% CI) in endothelial makers at age 60–64 years for overweight (BMI425 kgm− 2) vs normal weight, ﬁtted
separately for each age. Black lines indicate adjustment for age and sex only. Grey lines indicate further adjustment for overweight status at
age 60–64 years. CI, conﬁdence interval.
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changes in adipokines, it is logical that strengths of association
would be weaker. The absence of a consistent association
between overweight status and vWF is consistent with earlier
reports showing that vWF is less consistently associated with body
fatness than other endothelial function markers.30,31
The current report is also important in showing that not only
does being overweight at one period in time equate to more
adverse levels of adipokines and inﬂammatory markers but also
that continuing to stay overweight in adulthood will lead to
increasingly adverse levels of these adiposopathic markers. A large
number of randomised controlled trials have documented that
weight loss in adulthood (generally45%) can lead to lower levels
of leptin,17,18 CRP and IL-6 (refs 14,17) and higher levels of
adiponectin.14,17,18 Randomised controlled trials that did not
ﬁnd an effect of weight loss tended to be of short duration
(o8 weeks) or small sample sizes. In observational longitudinal
studies, the Cardiovascular Health Study found that weight loss in
elder adults over a 3-year period was associated with lower CRP,
whereas weight gain was associated with higher CRP,15 and
increases in waist circumference of Afro–Jamaican women over an
average of 4.1 years was associated with lower adiponectin
levels.16
Explanations for why the strength of associations between
overweight status and adiposopathic markers increased with age
are unknown. One possibility is that the estimates are actually the
same across adulthood, but that associations for earlier adult ages
appear weaker owing to BMI measurements being taken further
away in time from when the adiposopathic markers were
assessed. A more likely explanation is that study members who
were overweight at one age were likely to be overweight at the
next age (that is, tracking), with those overweight longer likely to
have higher BMIs on average;32 and hence there would be larger
differences in the adiposopathic markers between the overweight
and non-overweight groups at later ages. Tracking of overweight
over the life course is also why associations of overweight at
earlier years with markers were reduced after adjustment for
overweight at 60–64 years. Even with strong effects of overweight
at older ages, estimates after adjustment for current overweight,
and the results of the structured modelling approach, indicated
that overweight at periods earlier than 60–64 years were
important for adiposipathic marker levels at 60–64 years.
There was also evidence that differences in the adiposopathic
markers at age 60–64 years for overweight compared with non-
overweight widened over adulthood faster for some markers than
others. This is the explanation for why the best ﬁtting model
chosen for each adiposopathic marker was generally some form of
an accumulation model, but with heterogeneity in the type of
accumulation. For example, the best ﬁtting life course model
chosen for IL-6 was the strict accumulation model because
increases in associations were relatively small and consistent over
time. For adiponectin and leptin, increases in associations by age
increased stepwise from ages 15–36 to 60–64, resulting in a life
course model chosen where the effect of overweight accumulates
over time, but being overweight at older ages has more of an
effect than being overweight earlier in adulthood.
For E-selectin and t-PA, effects of overweight appeared to be
particularly strong for the cross-sectional measurement (60–64
years), but the possible inﬂuence of overweight at earlier periods
should not be discounted. Similar to the inﬂammatory and
endothelial markers, overweight during adolescence and adult-
hood was associated with the endothelial markers. That all
associations were explained by overweight at 60–64 suggests that
all relationships seen for overweight at earlier years could be due
to tracking of body fatness. However, the ﬁnding that model ﬁt for
the sensitive period at 60–64 and the accumulation models were
very similar suggests that overweight in adolescence and young
Figure 3. Percentage difference (95% CI) in inﬂammatory makers at age 60–64 years for overweight (BMI425 kgm− 2) vs normal weight, ﬁtted
separately for each age. Black lines indicate adjustment for age and sex only. Grey lines indicate further adjustment for overweight status at
age 60–64 years. CI, conﬁdence interval.
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adulthood are determinants of endothelial function in middle age,
but that overweight in middle age is the dominant inﬂuence.
Important strengths of this study were the availability of data on
a wide range of markers involved in the adiposopathic pathway
and prospective objective measures of height and weight across
the life course.33 We deﬁned overweight as a dichotomous
variable using a standard deﬁnition to facilitate the use of a
modelling approach that is an improvement over traditional
regression methods, in that we can attempt to disentangle how an
exposure might be linked to an outcome by comparing the ﬁt of
the data of two or more hypothesised life course models; as
compared with traditional regression that may miss an important
information by only testing one model at a time.28 For example, as
strengths of association between overweight and markers
increased with age, and associations were attenuated by
adjustment for overweight at 60–64 years, conclusions could be
made that overweight at earlier ages did not matter. However, the
method used in our paper shows that it is overweight at multiple
ages over adolescence and adulthood accumulating to produce
adipokine and inﬂammatory values in late middle age.
The life course modelling approach does have its limitations
however. For most of the adiposipathic markers, two or more of
the life course models explained the data as well as the saturated
model making it difﬁcult to determine a single best ﬁtting model.
We chose to interpret the model with the lowest AIC as the ‘best
ﬁtting’ life course model while also investigating models with
similar ﬁt. In reality, the processes linking excess body weight
across the life course to the adiposopathic markers may not
conform to any of the life course models speciﬁed here; if this
were the case, it would be impossible to identify the relevant
model from these analyses.28 Also, in order to maintain a
reasonable number of participants in each trajectory group, and
to reduce the potential multi-colinearity between multiple BMI
measurements, we dichotomised BMI using the standard cut-off
for overweight and only included three ages selected a priori to
represent three different periods of the life course. Although BMI
values at the three age points were correlated, the proportions of
variance in BMI at 60–64 years explained were low, particularly in
adolescence; directions of associations and variances were stable
in multivariable models. Findings were robust to the use of
alternative BMI cut-off values for overweight categories and all
alternative combinations of ages, with variance and direction of
estimates stable in multivariable models, suggesting the analysis
was not biased by these analytical decisions. The limitations of BMI
as a marker of body fatness are well known,34 particularly in
children, but it is a widely used measure easily applied to clinical
practise. As in any longitudinal study, attrition of the sample
occurred, despite high response rates.23 An advantage of using
the NSHD is the rich socioeconomic and health information that
has been collected from birth, allowing us to conﬁrm that results
did not differ appreciably when missing data were imputed from
current and prior data collections. The NSHD sample were all born
in England, Scotland and Wales in March 1946, before the main
immigration ﬂows, and therefore ﬁndings cannot be extrapolated
to the non-white British population, of whom only a small minority
of the are currently 60 years or older.22
In conclusion, we provide evidence that the longer an individual
is overweight during adolescence and adulthood, the more
adverse their level of adipokines and inﬂammatory markers at
60–64 years. Given that children alive today are likely to spend
more of their lives as overweight or obese than study members in
this study, with 33.9% of children in England currently being
overweight or obese by the age of 10–11 years,35 compared with
only 10.2% for NSHD at the same age;36 the differences seen in
these adiposopathic markers between overweight and normal
weight individuals could be even larger when current generations
reach retirement age. The results suggest that the prevention of
excess adiposity early in the life course could be important for theT
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prevention of CVD in adult life. In addition, many of these
adiposopathic risk factors are related to type 2 diabetes risk as well
as to CVD.37 Therefore, preventing the development of overweight
and obesity in early adult life or earlier could have appreciable
beneﬁt for the prevention of type 2 diabetes as well as CVD.
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